

**This Page Is Inserted by IFW Operations
and is not a part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Fig. 1




Fig. 2a




Fig. 2b




Fig. 2c





Fig. 2d






Fig. 3a




Fig. 3b

Fig. 3c





Fig. 4a

8 of 24




* B and T cells enriched or depleted
by magnetic activated cell sorting
(MACS) and complement lysis.

▨ Wild type mice
▤ "Spleen mice"

Fig. 4b

Host
 genotype






Fig. 5a




Fig. 5b

“T cell mice”








Fig. 5c

“Spleen mice”

Fig. 6



E μ enhancer/ IRF1 promoter



Albumin enhancer/promoter




Fig. 7




Fig. 8A-C





Fig. 8D



E




Haemalaun

FDC-M1
 (FITC)



PrP
 (TR)

PIS
 (TR)



Tg94/IRF



Tg33/lck



Prnp⁺



Prnp^{0/0}




Fig. 9A-C




Fig. 10





Fig. 11






Fig. 12A





Fig. 12B

Fig. 13



Prion Infectivity in Spleen of $Prnp^{+/-}$ mice after B- and T-cell depletion

A. Aguzzi
 S/N 09/554,567
 Diagnostic and Therapeutics for Transmissible
 Spongiform Encephalopathy and Methods for the
 Manufacture of Non-Infective Blood Products and
 Tissue Derived Products

24 of 24

